- Home
- ETNB vs ZYME Comparison
ETNB vs ZYME Comparison
Compare ETNB & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- ZYME
- Stock Information
- Founded
- ETNB 2018
- ZYME 2003
- Country
- ETNB United States
- ZYME United States
- Employees
- ETNB N/A
- ZYME N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- ZYME Health Care
- Exchange
- ETNB Nasdaq
- ZYME Nasdaq
- Market Cap
- ETNB 1.0B
- ZYME 846.1M
- IPO Year
- ETNB 2019
- ZYME 2017
- Fundamental
- Price
- ETNB $10.05
- ZYME $11.54
- Analyst Decision
- ETNB Strong Buy
- ZYME Buy
- Analyst Count
- ETNB 8
- ZYME 7
- Target Price
- ETNB $26.43
- ZYME $19.50
- AVG Volume (30 Days)
- ETNB 2.1M
- ZYME 449.0K
- Earning Date
- ETNB 05-01-2025
- ZYME 05-08-2025
- Dividend Yield
- ETNB N/A
- ZYME N/A
- EPS Growth
- ETNB N/A
- ZYME N/A
- EPS
- ETNB N/A
- ZYME N/A
- Revenue
- ETNB N/A
- ZYME $93,384,000.00
- Revenue This Year
- ETNB N/A
- ZYME $34.23
- Revenue Next Year
- ETNB N/A
- ZYME $68.78
- P/E Ratio
- ETNB N/A
- ZYME N/A
- Revenue Growth
- ETNB N/A
- ZYME 85.05
- 52 Week Low
- ETNB $4.16
- ZYME $8.21
- 52 Week High
- ETNB $11.84
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- ETNB 68.44
- ZYME 47.11
- Support Level
- ETNB $8.94
- ZYME $11.02
- Resistance Level
- ETNB $9.70
- ZYME $11.81
- Average True Range (ATR)
- ETNB 0.73
- ZYME 0.56
- MACD
- ETNB 0.14
- ZYME -0.03
- Stochastic Oscillator
- ETNB 93.78
- ZYME 32.04
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.